Supplementary Information

"Crmp4 deletion promotes recovery from spinal cord injury by neuroprotection and limited scar formation"

Jun Nagai^{1,2}, Yoshiteru Kitamura¹, Kazuki Owada¹, Naoya Yamashita³, Kohtaro Takei⁴, Yoshio Goshima³ and Toshio Ohshima^{1*}

¹ Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, 162-8480 Japan

² Research Fellow of Japan Society for the Promotion of Science

³ Department of Molecular Pharmacology and Neurobiology, Graduate School of

Medicine, Yokohama City University, Yokohama 236-0004, Japan

⁴ Department of Medical Life Science, Graduate School of Medical Life Science,

Yokohama City University, Yokohama, 236-0004, Japan.

* Corresponding author: Toshio Ohshima

Department of Life Science and Medical Bioscience, Waseda University,

2-2 Wakamatsu-cho Shinjuku-ku, Tokyo 162-8480, Japan

Tel: -81-3-5369-7321, Fax: -81-3-5369-7302, e-mail: ohshima@waseda.jp



Supplementary Fig. S1 Nagai et al.

Supplementary Fig. S2 Nagai et al.



а

Supplementary Fig. S3 Nagai et al.

3 mm rostral						
	2	3	4	5	6	7
Lesion epicenter						
8	9	10	11		13	
						3 mm caudal
	16	17	18	19	20	21
b						
3 mm rostral						
	2	3	4	5	6	7
Lesion epicenter						
8	9	10	11	12	13	14
						3 mm caudal
15	16	17	18	19	20	21

а

Supplementary Fig. S4 Nagai et al.



Supplementary Figure 1. CRMP4 deletion reduces non-traumatic inflammation. (a) Representative transverse images of thoracic spinal cords from mice with CRMP4 deletion stained with anti-Iba1 (marker for microglia/macrophages) and anti-GFAP (marker for astrocytes) antibodies at 3 days post induction of non-traumatic inflammation by Zymosan A. *, Zymosan A injection site; +, PBS injection site. Intraspinal micropipette insertion is confirmed to be non-traumatic by failure of PBS microinjection to activate microglia and astroglia. Scale bars = $1000 \,\mu$ m. (b, c) Areas of quantified microglial and astroglial activation in transverse sections taken every $300 \,\mu$ m around the injection site. n = 3. *, *P* < 0.05 compared with *Crmp4*+/+ controls. Statistical analysis by unpaired Student's *t* test. (d, e) Western blotting analysis with anti-Tumor necrosis factor alpha antibody after Zymosan A- or buffer-injection of spinal cords (n = 3 animals). **, *P* < 0.01. Statistical analysis by one-way ANOVA followed by Tukey's multiple comparison test. Data are mean ± S.E.M. PBS, phosphate-buffered saline; TNF α , Tumor necrosis factor alpha; NS, not significant.

Supplementary Figure 2. Serial cross sections from Crmp4+/+ and Crmp4-/- mice after SCI with myelin staining. Myelin staining of serial cross sections taken every 300 µm reveals demyelination through the lesion epicenter (#11). Sections #1–10 are rostral and #12–21 are caudal to the injury site. The left half of each spinal cord section illustrated is from a Crmp4+/+ mouse and the right half is from a Crmp4-/- mouse. The areas of myelin-positive white matter are not different among samples at 1 week post SCI, indicating that the dorsal transections to the animals were of uniform extent (**a**). However, at 4 weeks post injury, Crmp4-/- spinal cord exhibits significantly increased sparing of tissue, including white matter, when compared with control (**b**). The images of #11 and #14 are shown in Fig. 5d. Scale bar: 500 µm.

Supplementary Figure 3. Serial cross sections from Crmp4+/+ and Crmp4-/- mice after SCI with Nissl staining. Nissl staining of serial cross sections taken every 300 μ m reveals demyelination through the lesion epicenter (#11). Sections #1–10 are rostral and #12–21 are caudal to the injury site. The left halves of the spinal cord sections are from a Crmp4+/+ mouse and the right halves are from a Crmp4-/- mouse at 1 week post injury (**a**) or at 4 weeks post injury (**b**). The images of #11 and #16 are shown in Fig. 5c. Scale bar: 500 μ m.

Supplementary Figure S4. GAP43-immunolabeling in cross sections of injured spinal cords from *Crmp4+/+* and *Crmp4-/-* mice. Axonal growth in cross sections at 1.5 mm caudal to lesion site at 4 weeks after injury was detected by immunostaining with anti-GAP43 antibody. Although there was absent of GAP43-positive fibers at the location of descending corticospinal tracts in a control spinal cord (open arrows), GAP43 signals were apparent there in a *Crmp4-/-* spinal cord (arrows). Ascending fibers from dorsal root ganglion were GAP43-positive in both genotypes (arrowheads). Scale bar: 100 μm.

Supplementary Movie 1. Locomotor recovery after spinal cord injury in mice

lacking CRMP4. Example of a *Crmp4+/+* mouse demonstrating inability to move with hindlimbs and a *Crmp4-/-* mouse bearing its body weight at 4 weeks after spinal cord injury.